Relating to a study on prevention and reduction of diabetes-related amputation.

Contracts

• Payer-Provider Agreements: No immediate amendments required. However, General Counsels for hospital systems and insurers should draft contingency language for 2027 renewals, anticipating new reimbursement models tied to "amputation reduction" metrics derived from this study.
• University Collaboration: If your organization is a medical device manufacturer, prepare standard Memoranda of Understanding (MOUs) for data sharing with the designated Research 1 University to ensure your proprietary efficacy data is considered.

Hiring/Training

• Government Affairs: Reallocate resources to monitor the Texas Higher Education Coordinating Board (THECB) selection process. You must identify the lead University immediately upon designation.
• Clinical Data Teams: Task internal medical affairs teams with aggregating existing efficacy data for diabetic foot ulcer treatments to prepare for submission to the study committee.

Reporting & Record-Keeping

• Voluntary Data Submission: While no statutory reporting is required for private business, failing to submit your device or therapy's success rates to the study effectively excludes you from future "best practice" definitions.
• Audit Trails: Maintain a record of all correspondence with the designated University to establish a paper trail of cooperation should the final report exclude your therapy arbitrarily.

Fees & Costs

• No Statutory Fees: There are no new state fees or taxes associated with this bill.
• Lobbying/Research Costs: Budget for increased government relations and clinical data analysis expenses in Q1 and Q2 of 2026.